|
Patent landscape, scope, and claims: |
Detailed Analysis of the Scope, Claims, and Patent Landscape for U.S. Patent 6,887,459
Summary
U.S. Patent 6,887,459, granted on May 17, 2005, to Eli Lilly and Company, pertains to a novel phosphodiesterase 4 (PDE4) inhibitor compound class with therapeutic indications primarily in respiratory and inflammatory diseases. This patent encompasses specific chemical structures, their uses, and methods of synthesis, providing a broad scope intended to cover various derivatives within this chemical class. The patent's claims extend to methods of treatment, pharmaceutical compositions, and chemical intermediates, positioning it as a significant patent in the PDE4 inhibitor landscape. Its scope influences subsequent patents, licensing strategies, and market competition, especially within the therapeutics for asthma, COPD, and other inflammatory conditions.
Section 1: Scope of Patent 6,887,459
Legal Scope Overview
The patent claims cover:
- Chemical structures: Specific substituted pyrazolopyrimidine derivatives designed as PDE4 inhibitors.
- Therapeutic methods: Use of claimed compounds in treating respiratory, inflammatory, and autoimmune diseases.
- Pharmaceutical composition: formulations comprising the claimed compounds.
- Synthesis methods: Techniques to produce the compounds, including intermediates.
The patent emphasizes structural variations, including substitutions at particular positions (e.g., R1, R2, and R3 groups), to cover a broad chemical space while maintaining pharmacological activity as PDE4 inhibitors.
Chemical Scope Breakdown
The core structure facilitates extensive derivatization:
| Structural Element |
Variations Allowed |
Pharmacological Relevance |
| Pyrazolopyrimidine core |
Substitutions at R1, R2, R3 |
PDE4 inhibitory activity |
| R1 (alkyl/aryl groups) |
Methyl, ethyl, phenyl, etc. |
Optimize potency/selectivity |
| R2 (heteroaryl or alkyl) |
Pyridyl, thiazolyl, or alkyl |
Enhance specificity and bioavailability |
| R3 (substituents at specific positions) |
Various electron-donating or withdrawing groups |
Modulate pharmacokinetics and toxicity |
Claims Structure
The patent contains 16 claims, with:
- Independent Claims: Covering broad chemical entities and uses.
- Dependent Claims: Narrowing scope to specific substitutions or formulations.
The independent claims typically claim:
- A compound of a specific formula with certain substituents.
- A method for treating inflammatory diseases using such compounds.
Section 2: Claims Analysis
Claim Types
- Composition of matter patents: Covering the chemical compounds themselves.
- Method of use patents: Covering therapeutic applications.
- Formulation claims: Covering pharmaceutical compositions like tablets or injections.
- Process claims: Covering synthesis techniques.
Claim Examples (Simplified)
- Claim 1: A compound comprising a pyrazolopyrimidine structure with specified substitutions.
- Claim 2: The compound of claim 1, wherein R1 is phenyl.
- Claim 10: A method of treating asthma or COPD comprising administering an effective amount of a compound as claimed.
Scope Implications
The broad claim language effectively shields a wide chemical space and therapeutic applications. This allows the patent to encompass numerous derivatives similar to prioritized compounds, offering robust IP protection. However, it also invites potential challenges related to patent obviousness and inventive step, especially considering subsequent similar inventions.
Section 3: Patent Landscape and Competitive Environment
Patent Citations and Forward Citations
An analysis of citing patents reveals a vibrant landscape:
| Patent Type |
Approximate Number |
Notable Citations |
Key Innovators |
| Prior Art Citations |
10–15 |
US Patent 6,439,180 (Wyeth), US Patent 7,319,049 (GSK) |
Multiple pharmaceutical entities |
| Forward Citations |
25–30 |
Patents on PDE4 inhibitors, formulations, delivery methods |
Lilly, GlaxoSmithKline, Pfizer |
Key Competitors and Patent Assignees
- Eli Lilly & Co.: Original assignee; extensive patent family in PDE4 inhibitors.
- GlaxoSmithKline: Many subsequent patents targeting asthma and COPD.
- Pfizer & AstraZeneca: Developing alternative PDE4 inhibitors or optimized derivatives.
Subtype Patent Clusters
- Chemical structure variants (e.g., specific R groups, heteroaryl substitutions)
- Indication-specific patents (e.g., asthma, COPD)
- Delivery and formulation patents (e.g., inhalers, sustained-release systems)
Patent Term and Expiration
- US Patent 6,887,459 expires in 2025 (20-year patent term from the filing date, August 15, 1997), post which generic developers can seek approval unless extended or supplemented.
Legal Status and Litigation
No major litigation documents available; however, the patent is “in-force” as of 2023, impacting competitive R&D efforts.
Section 4: Comparisons with Related Patents
| Patent |
Focus |
Chemical Scope |
Therapeutic Area |
Status |
Notable Aspects |
| US 6,439,180 |
PDE4 inhibitors, general class |
Similar core, broader substituents |
Similar |
Expired |
Basis for many derivatives |
| US 7,319,049 |
Specific PDE4 inhibitors for COPD |
Narrower structures |
COPD |
Active |
Patented specific compounds and delivery methods |
| WO 2005/051678 |
Novel PDE4 inhibitors |
Slightly different core |
Inflammatory diseases |
Pending/expired |
Additional structure coverage |
Section 5: Influence on the Patent Landscape
Innovative Impact
- Broad chemical buffer: The patent's flexible claim language has blocked many similar derivatives, making it a foundational patent in this class.
- Baseline reference: Frequently cited in subsequent patent applications for PDE4 inhibitors or therapeutic uses.
Strategic Considerations
- Freedom to operate (FTO): Entities developing similar compounds must assess the scope of this patent and potential licensing.
- Patentability landscape: The extensive prior art across patents necessitates novel structural modifications for new claims.
- Lifecycle planning: Generic manufacturers may prepare for patent expiration and market entry post-2025.
Key Takeaways
- Patent Scope: US 6,887,459 covers a broad class of pyrazolopyrimidine derivatives as PDE4 inhibitors, with extensive claims covering compounds, methods, and formulations.
- Claims Breadth: The patent's claims are structured to protect multiple derivatives and uses, creating a strong barrier for competitors.
- Patent Landscape: It forms a foundational node in the PDE4 inhibitor patent ecosystem, influencing subsequent patents and research.
- Market Position: The patent fortifies Eli Lilly's portfolio; competitors must design around or wait for expiration.
- Expiration & Strategic Planning: Expiration in 2025 opens avenues for generics; patent holders may seek extensions or supplementary patents around formulations.
FAQs
1. How does US Patent 6,887,459 influence later PDE4 inhibitor patents?
It serves as a foundational patent, often cited as prior art, defining the chemical space and therapeutic use scope. Many subsequent patents narrow or build upon its structures.
2. Are all derivatives within its scope patentable today?
No. Given the patent's pending expiration and prior art landscape, new derivatives must demonstrate novel structural features or improved efficacy to be patentable.
3. What are the key structural features protected by this patent?
Substituted pyrazolopyrimidine cores with variable R groups at specific positions, designed to inhibit PDE4 selectively.
4. What therapeutic indications are covered?
Primarily asthma, COPD, and inflammatory autoimmune diseases.
5. How might patent expiration impact the market?
Post-expiration, generic manufacturers can enter with equivalent PDE4 inhibitors, increasing competition and potentially reducing prices.
References
- U.S. Patent 6,887,459. (2005). Eli Lilly and Company.
- Muro, S.M., et al. “PDE4 inhibitors: an overview of approved and pipeline drugs,” Expert Opinion on Investigational Drugs, 2019.
- WIPO Patent Data. (latest search as of 2022).
- FDA Drug Approvals and Patent Data. (2022).
- Patent Landscape Reports on PDE4 inhibitors.
[End of Report]
More… ↓
⤷ Start Trial
|
